LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Aandelen Lijst・Kura Oncology Inc

Kura Oncology Inc

Gesloten

SectorGezondheidszorg

8.74 -0.91

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.69

Max

9.1

Belangrijke statistieken
By Trading Economics
Inkomsten	7.7M -73M
Verkoop	929K 18M
EPS	-0.828
Winstmarge	-401.495
Werknemers	260
EBITDA	7.4M -78M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+219.07% upside

Dividenden
By Acuity
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-84M 760M
Vorige openingsprijs	9.65
Vorige sluitingsprijs	8.74

Nieuwssentiment

By Acuity

100%

320 / 344 Rangschikking in Healthcare

Kura Oncology Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 jun 2026, 23:36 UTC

Correction to Oracle Reports Higher 4Q Profit Article

10 jun 2026, 23:19 UTC

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

10 jun 2026, 23:09 UTC

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

10 jun 2026, 23:04 UTC

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

10 jun 2026, 20:44 UTC

Caterpillar Raises Quarterly Dividend 8%

10 jun 2026, 23:49 UTC

Elliott: Northern Star Should Take No Options Off The Table

10 jun 2026, 23:48 UTC

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

10 jun 2026, 23:48 UTC

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

10 jun 2026, 23:47 UTC

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

10 jun 2026, 23:47 UTC

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

10 jun 2026, 23:46 UTC

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

10 jun 2026, 23:38 UTC

Global Equities Roundup: Market Talk

10 jun 2026, 23:38 UTC

Global Forex and Fixed Income Roundup: Market Talk

10 jun 2026, 23:38 UTC

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

10 jun 2026, 23:32 UTC

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

10 jun 2026, 23:20 UTC

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

10 jun 2026, 22:05 UTC

Correction to Bank of Canada Stays on Hold Market Talk

10 jun 2026, 21:57 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 jun 2026, 21:52 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 jun 2026, 21:35 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 jun 2026, 21:22 UTC

Oracle Stock Slides on Increased Capital Spending -- WSJ

10 jun 2026, 20:50 UTC

Tech, Media & Telecom Roundup: Market Talk

10 jun 2026, 20:50 UTC

Financial Services Roundup: Market Talk

10 jun 2026, 20:50 UTC

Basic Materials Roundup: Market Talk

10 jun 2026, 20:50 UTC

Health Care Roundup: Market Talk

10 jun 2026, 20:39 UTC

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

10 jun 2026, 20:34 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 jun 2026, 20:33 UTC

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

10 jun 2026, 20:33 UTC

Global Equities Roundup: Market Talk

10 jun 2026, 20:33 UTC

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Peer Vergelijking

Prijswijziging

Kura Oncology Inc Prognose

Koersdoel

By TipRanks

219.07% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 28.11 USD 219.07%

Hoogste 40 USD

Laagste 15 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Kura Oncology Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Kura Oncology Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

320 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.